Skip to main content
Erschienen in: Pediatric Radiology 5/2005

01.05.2005 | Original Article

Bone densitometry in pediatric patients treated with pamidronate

verfasst von: Leslie E. Grissom, Heidi H. Kecskemethy, Steven J. Bachrach, Charles McKay, H. Theodore Harcke

Erschienen in: Pediatric Radiology | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Background: Increasing numbers of children are being treated with the bisphosphonate pamidronate for low bone mineral density, particularly children with increased risk of fractures caused by bone disorders or low/non-weight bearing. Objective: To determine the effect of intravenous pamidronate on the bone mineral density of children with osteogenesis imperfecta and spastic quadriplegic cerebral palsy. Materials and methods: Charts of 38 children with osteogenesis imperfecta (n=20) and spastic quadriplegic cerebral palsy (n=18) treated with pamidronate were retrospectively reviewed. Patients were selected for treatment because of prior fracture and/or abnormally low bone mineral density. All received intravenous pamidronate at two-month to eight-month intervals and were periodically examined using dual energy X-ray absorptiometry. Results: All patients had abnormally low bone mineral density prior to treatment. Lumbar spine bone mineral density and z-scores showed serial improvement in 31 of 32 patients. Spine bone mineral density increased 78±38.1% in OI and 47.4±39.0% in children with cerebral palsy. The area of greatest lateral distal femur bone mineral density improvement was in the metaphysis adjacent to the growth plate, with a 96±87.8% improvement in the osteogenesis imperfecta group and 65.7±55.2% improvement in the cerebral palsy group. Increases in bone mineral density exceeded that expected for age-specific growth. This was demonstrated by improvement in both spine and femur z-scores for both groups. No children with spastic quadriplegic cerebral palsy experienced fractures after the first week of treatment, whereas patients with osteogenesis imperfecta continued to have fractures but at a decreased rate. Conclusions: Intravenous pamidronate given at 3- to 4-month intervals proved to be effective in increasing bone mineral density in patients with osteogenesis imperfecta and spastic quadriplegic cerebral palsy. The greatest gains in bone mineral density were observed in the children with osteogenesis imperfecta, but they did continue to fracture, albeit at a decreased rate. Children with cerebral palsy gained bone mineral density and did not continue to fracture.
Literatur
1.
Zurück zum Zitat Henderson RC, Lark RK, Kecskemethy HH, et al (2002) Bisphosphonates to treat osteoporosis in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 141:644–651CrossRef Henderson RC, Lark RK, Kecskemethy HH, et al (2002) Bisphosphonates to treat osteoporosis in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 141:644–651CrossRef
2.
Zurück zum Zitat Glorieux FH, Bishop NJ, Plotkin H, et al (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952CrossRefPubMed Glorieux FH, Bishop NJ, Plotkin H, et al (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952CrossRefPubMed
3.
Zurück zum Zitat Falk MJ, Heeger S, Lynch KA, et al (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573–578CrossRef Falk MJ, Heeger S, Lynch KA, et al (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573–578CrossRef
4.
Zurück zum Zitat Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intraveneous pamidronate infusions. J Pediatr 4:417–423 Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intraveneous pamidronate infusions. J Pediatr 4:417–423
5.
Zurück zum Zitat Rauch F, Plotkin H, Zeitlin L, et al (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610–614PubMed Rauch F, Plotkin H, Zeitlin L, et al (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610–614PubMed
6.
Zurück zum Zitat Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696 Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696
7.
Zurück zum Zitat Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226–229PubMed Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226–229PubMed
8.
Zurück zum Zitat Devogelaer JP, Malghem J, Maldague B, et al (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360–363CrossRef Devogelaer JP, Malghem J, Maldague B, et al (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360–363CrossRef
9.
Zurück zum Zitat Harcke HT, Taylor A, Bachrach S, et al (1998) Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 28:241–246CrossRef Harcke HT, Taylor A, Bachrach S, et al (1998) Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 28:241–246CrossRef
10.
Zurück zum Zitat Henderson RC, Lark RK, Newman JE, et al (2002) Pediatric reference data for dual X-ray absorptiometric measures of bone density in the distal femur. AJR 178:439–443 Henderson RC, Lark RK, Newman JE, et al (2002) Pediatric reference data for dual X-ray absorptiometric measures of bone density in the distal femur. AJR 178:439–443
11.
Zurück zum Zitat Henderson RC (1997) Bone density and other possible predictors of fracture risk in children and adolescents with spastic quadriplegia. Dev Med Child Neurol 39:224–227PubMed Henderson RC (1997) Bone density and other possible predictors of fracture risk in children and adolescents with spastic quadriplegia. Dev Med Child Neurol 39:224–227PubMed
12.
Zurück zum Zitat Fleisch H (2000) Bisphosphonates in bone disease: from the laboratory to the patient, 4th edn. Academic Press, San Diego Fleisch H (2000) Bisphosphonates in bone disease: from the laboratory to the patient, 4th edn. Academic Press, San Diego
13.
Zurück zum Zitat Batch JA, Couper JJ, Rodda C, et al (2003) Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 39:88–92CrossRef Batch JA, Couper JJ, Rodda C, et al (2003) Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 39:88–92CrossRef
Metadaten
Titel
Bone densitometry in pediatric patients treated with pamidronate
verfasst von
Leslie E. Grissom
Heidi H. Kecskemethy
Steven J. Bachrach
Charles McKay
H. Theodore Harcke
Publikationsdatum
01.05.2005
Erschienen in
Pediatric Radiology / Ausgabe 5/2005
Print ISSN: 0301-0449
Elektronische ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-004-1393-3

Weitere Artikel der Ausgabe 5/2005

Pediatric Radiology 5/2005 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.